When to INDuce for OverWeight? (WINDOW)

NCT ID: NCT04603859

Last Updated: 2024-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-19

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background The World Health Organization (WHO) defines overweight as a body mass index (BMI) of ≥25 kg/m2 and obesity as a BMI of ≥30 kg/m2. Overweight and obesity are rising dramatically worldwide. In fertile women, the prevalence of obesity is one third in the United States, 20% in the United Kingdom, and 12-13% in Denmark. The association between obesity in pregnancy and the risk of gestational complications increases with increasing BMI. Among other complications, obesity in pregnancy is associated with increased risk of caesarean delivery. Delivery by caesarean section further adds significant risks of wound infection or other infectious morbidity in obese women as compared to normal weight women. The longer the woman is pregnant, the longer the risk of pregnancy complications remains. In an otherwise low-risk pregnant woman at term, it is an on-going clinical dilemma, whether the benefits of elective induction of labor (eIOL) and termination of the pregnancy will outweigh the potential harms from the concomitant induction and delivery process. Regarding delivery complications, based on data from historical cohorts, eIOL has traditionally been associated with an increased risk of caesarean section and instrumental delivery. Therefore, expectant management has been the preferred clinical option. This interpretation has now been challenged by a randomized trial (ARRIVE) with \>6000 low-risk pregnant women where eIOL at 39 weeks of gestation was associated with lower caesarean delivery rates. There are no randomized studies in obese women, but two larger observational studies did find lower odds of caesarean delivery in obese women with eIOL as compared to awaiting labor onset. Hence, a randomized trial that would compare caesarean delivery among obese women whose labor is induced with those expectantly managed is warranted. The proposed study will provide new and important knowledge into the area of induction of labor among overweight and obese women with potential great international impact for the future raising number of pregnant women in this subgroup.

With this trial, the investigators aim to compare the risk of caesarean section in obese (BMI ≥ 30 kg/m2), but otherwise low-risk women with eIOL as compared to expectant management.

Materials and methods

The study is a multicenter randomized controlled trial with an allocation ratio of 1:1 in the two following arms:

* Intervention arm/elective induction of labor in pregnancy at 39 gestational week and 0 to 3 days: Induction is performed according to local policy for induction of labor.
* Comparison arm/expectant management: Waiting for spontaneous onset of labor unless a situation develops necessitating either induction of labor or caesarean section.

1900 low-risk pregnant women with a pre- or early pregnancy BMI ≥ 30 carrying a singleton pregnancy will be recruited from the Danish delivery wards. In each trial site, a physician investigator will be responsible for the enrolment, the electronically randomization, and data collection.

The primary endpoint is the caesarean section rate. Among others there will be secondary endpoints on instrumental delivery, onset of labor, methods of induction, perinatal and postpartum complications both maternal and neonatal along with data on women's experience on birth measured by a questionnaire survey four to six weeks post-partum.

Ethics The study will be conducted in accordance with the ethical principles outlined in the latest version of the 'Declaration of Helsinki' and the 'Guideline for Good Clinical Practice' related to experiments on humans. The Central Denmark Region Committee on Biomedical Research Ethics, and The Danish Health Authorities have approved the study.

Perspectives In perspective, more than 39% of the world's population is overweight and 13% are obese by the WHO classification. Pregnant overweight women are at increased risk of pregnancy and delivery complications, and there is a need to improve maternity care for this subgroup of women. The results of this trial have the potential to generate important knowledge for the improvement of delivery in obese women and they will add key information to an on-going discussion of the effects of labor induction before term. Any possible harm or disadvantage to the individual study participant is outweighed by the possible benefit to the increasing number of obese women who will be pregnant in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Obesity Parturition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elective induction of labour

Elective induction of labour at 39 gestational weeks and 0 to 3 days.

Group Type EXPERIMENTAL

Elective induction of labor at 39 gestational weeks and 0 to 3 days

Intervention Type PROCEDURE

Elective induction of labor (eIOL) according to local policies

Expectant management

Awaiting spontaneous labor.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elective induction of labor at 39 gestational weeks and 0 to 3 days

Elective induction of labor (eIOL) according to local policies

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

eIOL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Pregnant women with pre- or early pregnancy BMI ≥ 30 kg/m2

Exclusion Criteria

* Legal or ethical considerations: maternal age \<18 years, language difficulties requiring an interpreter or translator
* Multiple pregnancy
* Previous caesarean section
* Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement
* Planned elective caesarean section at time of randomisation
* Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery
* Fetal contraindications to expectant management at time of randomisation
* Maternal contraindications to IOL at time of randomisation: e.g. placenta previa/accreta, vasa previa
* Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP\< 2 cm), signs of labour including pre-labour rupture of membranes (PROM)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aarhus University Hospital

OTHER

Sponsor Role collaborator

Randers Regional Hospital

OTHER

Sponsor Role collaborator

Herning Hospital

OTHER

Sponsor Role collaborator

Central Jutland Regional Hospital

OTHER

Sponsor Role collaborator

Nykøbing Falster County Hospital

OTHER

Sponsor Role collaborator

Odense University Hospital

OTHER

Sponsor Role collaborator

Rigshospitalet Juliane Marie Centret

UNKNOWN

Sponsor Role collaborator

Kolding Sygehus

OTHER

Sponsor Role collaborator

Herlev Hospital

OTHER

Sponsor Role collaborator

Hvidovre University Hospital

OTHER

Sponsor Role collaborator

North Zealand's Hospital

UNKNOWN

Sponsor Role collaborator

Zealand University Hospital - Roskilde

UNKNOWN

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lise Krogh

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lise Q Krogh, MD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Julie Glavind, MD, PhD

Role: STUDY_CHAIR

Aarhus University Hospital

Sidsel Boie, MD, PhD

Role: STUDY_CHAIR

Randers Regional Hospital

Jens Fuglsang, MD, PhD

Role: STUDY_CHAIR

Aarhus University Hospital

Tine B Henriksen, MD, PhD

Role: STUDY_CHAIR

Aarhus University Hospital

Jim Thornton, MD, PhD

Role: STUDY_CHAIR

Nottingham University

Katja A Taastrøm, Midwife, MSc

Role: STUDY_CHAIR

Aarhus University Hospital

Anne Cathrine M Kjeldsen, Midwife, MSc

Role: STUDY_CHAIR

Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital

Aarhus, , Denmark

Site Status RECRUITING

Rigshospitalet Juliane Marie Centre

Copenhagen, , Denmark

Site Status RECRUITING

Herlev Hospital

Herlev, , Denmark

Site Status RECRUITING

Gødstrup Regional Hospital

Herning, , Denmark

Site Status RECRUITING

North Zealand's Hospital

Hillerød, , Denmark

Site Status RECRUITING

Hvidovre Hospital

Hvidovre, , Denmark

Site Status RECRUITING

Kolding Hospital

Kolding, , Denmark

Site Status RECRUITING

Nykøbing Falster Hospital

Nykøbing Falster, , Denmark

Site Status RECRUITING

Odense University Hospital

Odense, , Denmark

Site Status RECRUITING

Randers Regional Hospital

Randers, , Denmark

Site Status RECRUITING

Zealand University Hospital

Roskilde, , Denmark

Site Status RECRUITING

Viborg Hospital

Viborg, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lise Q Krogh, MD

Role: CONTACT

0045 51242102

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lise Q Krogh, MD

Role: primary

Kristina Renault, MD, DMSc

Role: primary

Lene Huusom, MD, PhD

Role: primary

Iben Sundtoft, MD, PhD

Role: primary

Hanne B Westergaard, MD, PhD

Role: primary

Lone Krebs, MD, PhD

Role: primary

Anne Cathrine H Munk, MD

Role: primary

Jeannet Lauenborg, MD, PhD

Role: primary

Christina Vinter, MD, PhD

Role: primary

Pinar Bor, MD, PhD

Role: primary

Nana Wiberg, MD

Role: primary

Lise Clausen, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Krogh LQ, Boie S, Henriksen TB, Thornton J, Fuglsang J, Glavind J. Induction of labour at 39 weeks versus expectant management in low-risk obese women: study protocol for a randomised controlled study. BMJ Open. 2022 Apr 25;12(4):e057688. doi: 10.1136/bmjopen-2021-057688.

Reference Type DERIVED
PMID: 35470194 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan: Study Protocol including Statistical Analysis Plan

View Document

Document Type: Statistical Analysis Plan: Detailed Statistical Analysis Plan (separate)

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WINDOW

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Birth Environment of the Future
NCT02478385 COMPLETED NA
Up-Down Oxytocin Infusion
NCT00785395 COMPLETED PHASE4
Induction ATAD Catheter and Lower Segment Thickness
NCT06187779 ACTIVE_NOT_RECRUITING NA